Technology | May 15, 2015

Application highlights evidence-based treatment options at the point of care

McKesson Specialty Health, Guideline Explorer, cancer, iPad, Clear Value Plus

May 15, 2015 — McKesson Specialty Health announced the availability of Clear Value Plus – Guideline Explorer to iPad users. The Guideline Explorer app is a mobile reference tool that gives users access to evidence-based cancer protocols based on patient attributes.

Available for download on the Apple App Store at no cost, the Guideline Explorer app provides users with an easy-to-use interface for exploring patient-specific treatment options based on the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guidelines) and Value Pathways powered by NCCN. Current Clear Value Plus users can access the complete range of evidence-based treatment options and see all treatment choices that are highlighted as part of the Value Pathways powered by NCCN. New iPad users can navigate NCCN Content and explore chemotherapy regimens based on specific patient characteristics and quickly view up-to-date chemotherapy options, as well as known side effect profiles.

The new iPad tool is an extension of McKesson Specialty Health’s Clear Value Plus, a quality support tool for oncologists that highlights evidence-based treatment options at the point of care. The software brings to life Value Pathways powered by NCCN and NCCN Guidelines within the clinical workflow—offering evidence-based protocols at the point of care with the patient. In addition, Clear Value Plus is compatible with multiple provider systems and provides integrated financial information, real-time reporting and benchmarking to demonstrate the value of delivering evidence-based care.

For more information: www.mckessonspecialtyhealth.com

Related Content

News | Prostate Cancer

August 16, 2022 — A new study published by University of Kentucky Markey Cancer Center researchers suggests that the ...

Time August 16, 2022
arrow
News | Breast Imaging

August 15, 2022 — Brainlab announced the first group of breast cancer patients treated in United States with the ...

Time August 15, 2022
arrow
News | Lung Imaging

August 10, 2022 — Mount Sinai is leading a team of lung cancer researchers that has been awarded a three-year, $500,000 ...

Time August 10, 2022
arrow
News | Breast Imaging

August 8, 2022 — The U.S. Food and Drug Administration approved Enhertu (fam-trastuzumab-deruxtecan-nxki), an IV ...

Time August 08, 2022
arrow
News | Lung Imaging

August 8, 2022 — Representatives from the Diagnostics Working Group of the IASLC Early Detection and Screening Committee ...

Time August 08, 2022
arrow
News | Lung Imaging

August 8, 2022 — A clinical trial is only as powerful as its participants. For years, researchers have struggled to fill ...

Time August 08, 2022
arrow
News | Proton Therapy

August 5, 2022 — IBA (Ion Beam Applications S.A., EURONEXT), a world leader in particle accelerator technology, Fred ...

Time August 05, 2022
arrow
News | Lung Imaging

August 3, 2022 — Structural differences in lung airways between men and women may be the cause of differences in chronic ...

Time August 03, 2022
arrow
Feature | Oncology Information Management Systems (OIMS)

August 2, 2022 — The oncology information systems market is projected to be worth $2.59 Bn by 2022 and is expected to ...

Time August 02, 2022
arrow
Feature | Lung Imaging

August 1, 2022 — In recognition of World Lung Cancer Day, the American Lung Association announced new patient resources ...

Time August 01, 2022
arrow
Subscribe Now